Evidence map›Paper›PMID 41597257›Full record

ArticleCells2026

PD-L1 and BAP1 as Prognostic Biomarkers in Malignant Pleural Mesothelioma.

Milija Gajić, Vesna Ćeriman Krstić, Natalija Samardžić, Ivan Soldatović, Sofija Glumac, Milena Jovanović, Milan Savić, Mihailo Stjepanović, Spasoje Popević, Ruža Stević and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Milija GajićClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0009-0005-2953-2099
Vesna Ćeriman KrstićClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0002-6661-9346
Natalija SamardžićClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Ivan SoldatovićInstitute of Medical Statistics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Sofija GlumacDepartment of Pathology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-2720-4148
Milena JovanovićDepartment of Pathology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-4781-711X
Milan SavićFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-0425-0731
Mihailo StjepanovićClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0003-1787-1438
Spasoje PopevićClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0002-3587-4029
Ruža StevićFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0003-3286-3663
Nikola ČolićFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0001-6516-1970
Katarina LukićCenter for Radiology, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0009-0001-4861-4189
Vladimir MilenkovićFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Ivan MilivojevićClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0000-0002-3289-8148
Ivana Sekulović RadovanovićClinic for Pulmonology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.ORCID 0009-0009-1220-3896
Dragana JovanovićInternal Medicine Clinic "Akta Medica", 11000 Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant pleural mesothelioma (MPM) is a very aggressive tumor. The prognostic value of PD-L1 and BAP1 expression has been investigated in many studies. A retrospective study was conducted that analyzed PD-L1 and BAP1 expression as prognostic biomarkers in patients with MPM. The study included 53 patients with MPM. PD-L1 expression ≥ 1% was found in 39.6%, and BAP1 loss was found in 81.1% of patients. The median overall survival (mOS) was 11 months. Subtype of MPM (

Indexed as

B7-H1 AntigenBiomarkers, TumorMesothelioma, MalignantPleural NeoplasmsTumor Suppressor ProteinsUbiquitin ThiolesteraseAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesB7-H1 AntigenBAP1 protein, humanBiomarkers, TumorCD274 protein, humanTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1malignant pleural mesotheliomaPD-L1prognostic biomarker

Identifiers

PMID41597257
PMCPMC12839189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.